---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015654"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:53:39.190994+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Processa prices $7M public offering of common stock and warrants at $0.25/unit

## Summary
- Gross proceeds of $7M before expenses; offering of 28M shares/pre-funded warrants plus 28M common warrants.
- Combined price $0.25 per share (or pre-funded warrant) and accompanying common warrant.
- Common warrants exercisable at $0.25/share for 5 years, immediately exercisable.
- Net proceeds to fund Phase 2 trial of NGC-Cap and for working capital & general corporate purposes.
- H.C. Wainwright acted as placement agent; receives 7% cash fee and 1.12M Placement Agent Warrants.

## SEC filing metadata
- accession: 0001641172-25-015654
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/0001641172-25-015654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015654
- JSON: https://secwatch.observer/filing/0001641172-25-015654.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.